Therapeutics development for triplet repeat expansion diseases

被引:118
作者
Di Prospero, NA [1 ]
Fischbeck, KH [1 ]
机构
[1] NINDS, Neurogenet Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1038/nrg1690
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The underlying genetic mutations for many inherited neurodegenerative disorders have been identified in recent years. One frequent type of mutation is trinucleotide repeat expansion. Depending on the location of the repeat expansion, the mutation might result in a loss of function of the disease gene, a toxic gain of function or both. Disease gene identification has led to the development of model systems for investigating disease mechanisms and evaluating treatments. Examination of experimental findings reveals similarities in disease mechanisms as well as possibilities for treatment.
引用
收藏
页码:756 / 765
页数:10
相关论文
共 134 条
[1]   NR2A and NR2B receptor gene variations modify age at onset in Huntington disease [J].
Arning, L ;
Kraus, PH ;
Valentin, S ;
Saft, C ;
Andrich, J ;
Epplen, JT .
NEUROGENETICS, 2005, 6 (01) :25-28
[2]   Friedreich's ataxia:: Idebenone treatment in early stage patients [J].
Artuch, R ;
Aracil, A ;
Mas, A ;
Colomé, C ;
Rissech, M ;
Monrós, E ;
Pineda, M .
NEUROPEDIATRICS, 2002, 33 (04) :190-193
[3]   Motor and cognitive improvements in patients with Huntington's disease after neural transplantation [J].
Bachoud-Lévi, A ;
Rémy, P ;
Nguyen, JP ;
Brugières, P ;
Lefaucheur, JP ;
Bourdet, C ;
Baudic, S ;
Gaura, V ;
Maison, P ;
Haddad, B ;
Boissé, MF ;
Grandmougin, T ;
Jény, R ;
Bartolomeo, P ;
Dalla Barba, G ;
Degos, JD ;
Lisovoski, F ;
Ergis, AM ;
Pailhous, E ;
Cesaro, P ;
Hantraye, P ;
Peschanski, M .
LANCET, 2000, 356 (9246) :1975-1979
[4]   Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms [J].
Bailey, CDC ;
Johnson, GVW .
JOURNAL OF NEUROCHEMISTRY, 2005, 92 (01) :83-92
[5]   Experimental therapeutics in transgenic mouse models of Huntington's disease [J].
Beal, MF ;
Ferrante, RJ .
NATURE REVIEWS NEUROSCIENCE, 2004, 5 (05) :373-384
[6]   REPLICATION OF THE NEUROCHEMICAL CHARACTERISTICS OF HUNTINGTONS-DISEASE BY QUINOLINIC ACID [J].
BEAL, MF ;
KOWALL, NW ;
ELLISON, DW ;
MAZUREK, MF ;
SWARTZ, KJ ;
MARTIN, JB .
NATURE, 1986, 321 (6066) :168-171
[7]   The mGIuR theory of fragile X mental retardation [J].
Bear, MF ;
Huber, KM ;
Warren, ST .
TRENDS IN NEUROSCIENCES, 2004, 27 (07) :370-377
[8]  
BEISTER A, 2004, J NEURAL TRANSM, V68, pS117
[9]   Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer [J].
Bemelmans, AP ;
Horellou, P ;
Pradier, L ;
Brunet, I ;
Colin, P ;
Mallet, J .
HUMAN GENE THERAPY, 1999, 10 (18) :2987-2997
[10]   Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor:: Results of a phase I study [J].
Bloch, J ;
Bachoud-Lévi, AC ;
Déglon, N ;
Lefaucheur, JP ;
Winkel, L ;
Palfi, S ;
Nguyen, JP ;
Bourdet, C ;
Gaura, V ;
Remy, P ;
Brugières, P ;
Boisse, MF ;
Baudic, S ;
Cesaro, P ;
Hantraye, P ;
Aebischer, P ;
Peschanski, M .
HUMAN GENE THERAPY, 2004, 15 (10) :968-975